Edgewise Therapeutics Inc

NASDAQ EWTX

Data sourced from iex and EODHD
Download Data

Edgewise Therapeutics Inc Income Statement 2020 - 2024

This table shows the Income Statement for Edgewise Therapeutics Inc going from 2020 until 2024. The income statement, also known as the profit and loss statement, is a financial statement that provides a summary of a company's revenues, expenses, and net income over a specific period (such as a quarter or a year). It shows the company's ability to generate revenue, manage expenses, and ultimately determine its profitability.
Income Statement Trend Unit 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31
Revenue
M 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Cost of Revenue
M 1 1 0 0 0 - - - - - - - - - - - -
Gross Profit
M -1 2 0 0 0 - - - - - - - - - - - -
Operating Expenses
M 34 36 29 25 25 - - - - - - - - - - - -
Selling, General, and Administrative Expenses (SG&A)
M 7 6 6 6 6 5 4 4 4 4 3 3 1 1 0 0 0
Research and Development (R&D) Expenses
M 27 28 24 20 20 17 14 12 11 9 10 8 5 5 3 4 3
Other Operating Expenses
M 0 2 0 0 0 - - - - - - - - - - - -
Costs and Expenses
M 34 33 29 25 25 - - - - - - - - - - - -
Operating Income
M -35 -34 -29 -25 -26 -22 -18 -16 -15 -13 -13 -10 -7 -6 -4 -4 -3
Interest Expense
M - 3 - - -3 3 1 0 0 0 0 0 0 0 0 0 0
Non-operating Income/Expense
M 6 4 4 4 3 3 1 0 0 43 0 0 0 0 0 0 0
EBT
M -29 -30 -26 -21 -23 -19 -17 -16 -15 -13 -13 -10 -7 -6 -4 -4 -3
Income Tax Provision
M - 4 0 - -3 -3 -1 0 0 43 - - - - - - -
Income after Tax
M - -34 -25 - -20 -17 -17 -16 -14 -56 - - - - - - -
Non-Controlling Interest
M - - - 0 0 0 0 0 0 0 0 0 0 - 0 0 0
Net Income
M - - - -21 -23 -19 -17 -16 -15 -13 -13 -10 -7 - -4 -4 -3
Shares (Basic, Weighted)
M - - - - - - - - - - - - - - - - -
Shares (Diluted, Weighted)
R 87,567,307.00 64,774,775.00 63,459,560.00 63,380,430.00 63,265,800.00 53,593,753.00 51,844,904.00 49,622,752.00 49,544,589.00 49,264,938.00 49,264,938.00 49,258,449.00 1,559,868.00 20,338,136.00 20,338,136.00 20,338,136.00 20,338,136.00
EBITDA
M -34 -33 -29 -25 -26 -22 -18 -16 -15 -13 -13 -10 -7 -6 -4 -4 -3
Depreciation and Amortization
M 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
EBIT
M -35 -34 -30 -25 -26 -22 -18 -16 -15 -13 -13 -10 -7 -6 -4 -4 -3
Income from Discontinued Operations
M - - - - - - - - - - - - - - - - -
Tax Rate (Effective)
% - -11.96 1.93 - 13.60 13.72 4.37 2.64 1.13 -337.22 - - - - - - -
Earnings Per Share (EPS), Basic
M - - - - - - - - - - - - - - - - -
Earnings Per Share (EPS), Diluted
M - - - 0 0 0 0 0 0 0 0 0 0 - 0 0 0
Gross Profit Margin
% - 76.33 - - - - - - - - - - - - - - -
Operating Income Margin
% - -1,503.64 - - - - - - - - - - - - - - -
Net Income Margin
% - - - - - - - - - - - - - - - - -
EBITDA Ratio
% - -1,479.97 - - - - - - - - - - - - - - -
EBIT Ratio
% - -1,503.64 - - - - - - - - - - - - - - -
EBT Ratio
% - -1,338.50 - - - - - - - - - - - - - - -

StockViz Staff

September 16, 2024

Any question? Send us an email